The presence of activins in those hypothalamic regions containing gonadotropin-releasing hormone (GnRH)-secreting neurons suggests that these peptides may regulate the reproductive function modulating not only pituitary FSH release and biosynthesis, but also hypothalamic GnRH release. The purpose of this study was to evaluate the effects of activin-A, a homodimer of inhibin A subunit, on hypothalamic GnRH release in vitro and, because of their well known antithetical effects, to evaluate its interaction with inhibin. In addition, since androgens modulate the release of GnRH from male rat hypothalami, we thought it of interest to study the possible interplay between these steroids and activin on GnRH release. To accomplish this, we employed a hypothalamic organ culture system which enabled us to evaluate GnRH release from individually incubated hemi-hypothalami explanted from male rats. Activin-A stimulated GnRH release in a biphasic manner. The maximal effect was reached at a concentration of 10 ng/ml which increased GnRH output by about 75%. Inhibin abolished the stimulatory effect of a maximally effective concentration of activin-A in a dose-dependent manner, whereas alone it had no effect on GnRH output. As previously shown, testosterone (1 nmol/l) and dihydrotestosterone (DHT, 0·1 nmol/l) suppressed basal GnRH release, but only testosterone was able to inhibit the release of GnRH stimulated by activin-A. Since DHT is a non-aromatizable androgen, we evaluated whether the inhibitory effect of testosterone was due to its in vitro conversion into 17 -estradiol. The addition of 4-hydroxyandrostenedione, a steroidal aromatase inhibitor, did not influence the suppressive effect of testosterone on GnRH release stimulated by activin-A.
Introduction
Activins and inhibins are dimer glycoproteins sharing a common -subunit. Inhibin is a heterodimer of an inhibin-specific -subunit and one of the two closely related -subunits ( A or B ), thus forming two different inhibins: inhibin-A and inhibin-B. Activins originate from the dimerization of two -subunits. Hence, they exist in three different molecular forms: activin-A, a homodimer of the A subunit, activin-B, a homodimer of the B subunit, and activin-AB, a heterodimer (see Ying 1988 for review) .
Activins and inhibins were initially identified for their capability to stimulate and inhibit, respectively, the release of pituitary follicle-stimulating hormone (FSH) (Ling et al. 1985 , 1986 , Rivier et al. 1985 , Vale et al. 1986 . Although these glycoproteins were first isolated from the gonads, they were since found to be widely distributed and it was hypothesized that they may also act on the hypothalamus indirectly to regulate FSH secretion (Franchimont et al. 1989) . The presence of A and B subunit-containing neurons in the septal and preoptic regions of the hypothalamus, where gonadotropinreleasing hormone (GnRH)-containing neurons are mainly located, suggests that activins may participate in the regulation of GnRH release . More recently, the activin receptor ActRII has been found expressed in several hypothalamic areas involved in neuroendocrine regulation, such as the suprachiasmatic, supraoptic, paraventricular, and arcuate nuclei (Cameron et al. 1994) , adding further circumstantial evidence for a possible physiological role of activins at the hypothalamic level. These observations prompted us to examine the effects of activin-A on GnRH release by employing a hypothalamic organ culture system which enabled us to study GnRH release from individually incubated hemihypothalami explanted from male rats. Given that activins and inhibins exert antithetical effects (Ying 1988) , we evaluated their interaction on GnRH release. Moreover, based on the observation that testosterone and its 5 -reduced derivative dihydrotestosterone (DHT) suppress GnRH release (Calogero et al. 1993) , we also examined whether these androgens may modulate the effects of activin-A on GnRH release in vitro.
Materials and Methods

Materials
Human recombinant activin-A was generously donated by Genentech Inc. (South San Francisco, CA, USA). Bovine inhibin was purchased from Peninsula Laboratories Europe Ltd (St Helens, Merseyside, UK). Testosterone and DHT were purchased from Sigma Chimica (Milan, Italy). 4-Hydroxyandrostenedione (4OH-A, CGP-31349) was a gift from Ciba-Geigy S.p.A. (Origgio, VA, Italy).
125 ILabeled GnRH was purchased from New England Nuclear (Boston, MA, USA). Steroids were solubilized in absolute ethanol and the highest concentration of ethanol used in the tissue culture was 0·01%. At this concentration, ethanol did not have any detectable effect on GnRH release (data not shown).
Removal and incubation of hypothalami
Experiments were performed using intact male SpragueDawley rats weighing 200-225 g (8-9 weeks old) (Charles River, Calco, CO, Italy). Animals were housed for 4-5 days in a temperature-controlled room (22 C) with lights on from 0700 to 1900 h. Rat chow and tap water were available ad libitum. The rats were killed by decapitation and hypothalami explanted and halved longitudinally as previously reported (Calogero et al. 1993) . The hemihypothalami (one tissue per well, 48-multiwell plates; Costar, Cambridge, MA, USA) were placed in a waterjacketed incubator at 37 C under an atmosphere of 95% air and 5% CO 2 . Preincubation and incubation were carried out using medium-199 with modified Earle's salt (Gibco, Paisley, Strathclyde, UK) containing 0·1% bovine serum albumin (fraction V; Sigma) and 20 µmol/l bacitracin (zinc salt, Aldrich, Milwaukee, WI, USA) (M199).
Experimental protocols
The hemi-hypothalami were preincubated for 30 min in M199 before the experiments were run. The experimental design consisted of 2 passages of the hemi-hypothalami into different wells (one hemi-hypothalamus/0·5 ml) every 6 h (total length of the experiment 12 h). This interval of incubation was selected on the basis of preliminary studies which showed that activin-A had no effect after 45 min and 2 h of incubation (data not shown), but was fully effective after 6 h. Tissue transfer from one well to the other was carried out with a 3 3 mm nylon mesh grid (nylon monofilament 44 µ; Small Parts, Miami, FL, USA). In the second well, a number of hemi-hypothalami for each experiment were exposed to a depolarizing concentration (60 mmol/l) of potassium chloride (KCl) to test tissue viability by identifying the GnRH response. Three different protocols were used in this study.
Protocol 1 was designed to evaluate the effects of activin-A, inhibin, testosterone and DHT upon unstimulated GnRH release. For this purpose, each hemihypothalamus was incubated in M199 without test substance in the first well (the concentration of GnRH was used as basal GnRH release for that given tissue) and exposed to graded concentrations of activin-A or inhibin and to 1 nmol/l testosterone or 0·1 nmol/l DHT in the second well (treated GnRH release). The effects of the zero concentration of activin-A, inhibin, testosterone, and DHT were evaluated by incubating the hemihypothalami with M199 alone also in the second well.
Protocol 2 was designed to evaluate the effects of inhibin, testosterone, and DHT on activin-A (10 ng/ml)-stimulated GnRH release. For this purpose, the hemihypothalami were incubated in M199 without test substance in the first well (basal GnRH release) and exposed to graded concentrations of inhibin plus activin-A, testosterone (1 nmol/l) plus activin-A or DHT (0·1 nmol/l) plus activin-A in the second well (treated GnRH release). The effect of activin-A alone was determined by incubating the hemi-hypothalami allocated to this treatment in M199 containing 10 ng/ml activin-A in the second well.
Protocol 3 was designed to evaluate the effect of 4OH-A on testosterone-suppressed, activin-A-stimulated GnRH release. For this purpose, the hemi-hypothalami were incubated in M199 alone in the first well (basal GnRH release) and incubated with activin-A (10 ng/ml) alone, activin-A (10 ng/ml) plus testosterone (1 nmol/l) or activin-A (10 ng/ml) plus testosterone (1 nmol/l) plus 4-OH-A (1 µmol/l) in the second well (treated GnRH release).
GnRH radioimmunoassay
The concentration of GnRH in the incubation medium was measured by RIA as previously reported (Calogero et al. 1993) . Standard solutions and medium samples were measured in duplicate. GnRH antiserum, used at a final dilution of 1:15 000, bound 40·8 1·9% (n=14) 125 I-GnRH (]3200 c.p.m.). Nonspecific binding was 1·98 0·11%. The sensitivity (ED 90 ) of the assay was 4·64 0·28 pg/ml (1·16 0·07 pg/well). The intra-assay and interassay coefficients of variation were 2·8 0·2% and 10·3% respectively.
Analysis of data
The results (means ...) were calculated as percentage of basal GnRH release from each tissue applying the following formula: GnRH(%)=treated GnRH release divided by basal GnRH release multiplied by 100. Statistical evaluation was performed by one-way analysis of variance (ANOVA) followed by Duncan's multiple range test. Significance was accepted at a P value lower than 0·05.
Results
The mean ( ...) GnRH basal release during the first 6 h of incubation was 11·3 1·4 pg/well, whereas the release of GnRH during the second 6 h of incubation in M199 alone was 13·9 1·5 pg/well (133·5 4·9% of basal). Those hemi-hypothalami which were exposed to 60 mmol/l KCl in the second well increased their GnRH output by 362·4 15·3% of basal. This effect disappeared in the presence of the calcium channel blocker verapamil (10 µmol/l), suggesting that KCl-induced GnRH release was calcium-dependent (data not shown). Activin-A stimulated hypothalamic GnRH release in a biphasic manner (Fig. 1a) . The greatest effect was achieved at 10 ng/ml (5 ng/well) when GnRH output was increased by about 75%. Activin-A was less effective at higher concentrations. Given the antithetical effects of activin and inhibin, we tested whether the latter had any effect on activin-A-stimulated GnRH release. The results of these experiments showed that inhibin suppressed, dosedependently, the release of GnRH stimulated by a maximally effective concentration of activin-A (Fig. 2) . The lowest effective concentration of inhibin was 10 ng/ml which reduced GnRH release by about 35%. At a higher concentration (20 ng/ml), inhibin suppressed completely the stimulatory effect of activin-A. Inhibin did not have any effect upon unstimulated GnRH release (Fig. 1b) .
Because of the reported inhibitory effect of testosterone and DHT on hypothalamic GnRH release (Calogero et al. 1993) , we tested whether these androgens were able to modulate the effects of activin-A on GnRH release. Testosterone, at a concentration of 1 nmol/l, suppressed both unstimulated and activin-A (10 ng/ml)-stimulated GnRH release (Fig. 3, open bars) . On the other hand, DHT, at a concentration of 0·1 nmol/l, suppressed unstimulated, but not activin-A-stimulated GnRH release (Fig. 3, solid bars) . We also evaluated whether inhibition of aromatase activity would have any consequence on the inhibitory effect of testosterone. The addition of 4OH-A, a steroidal aromatase inhibitor, did not influence the suppressive effect of testosterone on GnRH release stimulated by activin-A (Fig. 4) . 
Discussion
The effects of activin on pituitary FSH biosynthesis and release are well known (see Ying 1988 for review). Activin-A produces a dose-dependent release of FSH and a parallel increment of the FSH -subunit mRNA from pituitary cell cultures. This effect is completely overridden by inhibin and takes at least 4 h to become evident. No effect is detected on luteinizing hormone (LH) release and on LH -and -subunit mRNA expression (Carroll et al. 1989 , Corrigan et al. 1991 . In addition, activin potentiates the effects of GnRH on FSH, but not LH, release (Ling et al. 1986 , Vale et al. 1986 . A monoclonal antibody against activin-B, added to a primary culture of anteropituitary cells, decreases FSH release and FSH -subunit mRNA expression, suggesting that activin may play an autocrine role in the regulation of FSH release (Corrigan et al. 1991) . Activin is also able to increase FSH serum levels in the whole animal with a maximal serum FSH increment observed after 4 h (Carroll et al. 1991 , Doi et al. 1991 , Rivier & Vale 1991 . Previous administration of GnRH antagonists does not prevent the stimulatory effect of activin-A, whereas inhibin reverses it (Rivier & Vale 1991) . Interestingly, activin-A is devoid of effect on FSH release and biosynthesis in immature and ovariectomized female rats, but becomes fully effective after 17 -estradiol (E 2 ) replacement therapy (Carroll et al. 1991) .
In addition to a pituitary site of action, effects of activins and inhibins on the release and/or biosynthesis of hypothalamic GnRH release have been suggested (Lumpkin et al. 1981 , Condon et al. 1983 , Greef et al. 1983 . The recent demonstration that -subunits and the activin receptor ActRII mRNA are present in hypothalamic regions involved in the release of GnRH provided the neuroanatomical basis for a possible effect of activins on GnRH release and/or biosynthesis , Cameron et al. 1994 . Accordingly, Gonzalez-Manchion and co-workers (1991) found that activin-A is able to stimulate, in a concentration-and time-dependent fashion, the release of GnRH from the GnRH-secreting cell line GT1-7. The maximal effect (50% stimulation) was achieved after two days of incubation with activin-A and was partially suppressed (by about 30%) by the co-incubation with inhibin. Interestingly, the secretory effect of activin-A was accompanied by a change in the cellular morphology to a more neuronal phenotype. Our findings, obtained from an experimental model employing a tissue with a preserved structure, confirmed that activin-A is able to stimulate GnRH release. However, in contrast to the study employing the GT1-7 cell line (Gonzalez-Manchion et al. 1991) , the maximal effect attained was stronger, it was obtained at a lower concentration (i.e. 10 vs 20 ng/ml), and it required only 6 h of incubation to became evident. In addition, inhibin was able to overcome completely the stimulation induced by activin-A. The preserved tissue integrity of our hypothalamic explants (Calogero et al. 1989 ) may explain the more pronounced effects of activin and inhibin described in this study. This has been proven true for the pituitary gland, since intact hemi-pituitaries exhibit a greater hormonal responsiveness than dispersed pituitary cells (Milenkovic et al. 1989) . Despite early studies suggesting a hypothalamic site of inhibin action (Lumpkin et al. 1981 , Condon et al. 1983 , Greef et al. 1983 , we and others (Gonzalez-Manchion et al. 1991 , Knight 1996 have been unable to find any effect of inhibin on basal GnRH release. This finding may support the hypothesis that the main site of inhibin action is the pituitary (Tilbrook et al. 1993) .
Gonadal steroids play a relevant role in the functional activity of the hypothalamic GnRH-secreting neuron. Indeed, it has been suggested that the negative feedback action of testosterone is mainly exerted on the release of hypothalamic GnRH (Plant 1986 , Tilbrook et al. 1993 . We reported that this steroid suppresses GnRH release in a dose-dependent manner (Calogero et al. 1993) . The finding that testosterone also suppressed the effects of activin-A on GnRH release indicates a more extensive negative feedback influence. The observation that GnRH neurons apparently lack steroid receptors (Huang & Harlan 1993) raises the question whether the effects of testosterone are mediated by other interneuronal pathways, although recent work has challenged this tenet (Poletti et al. 1994) . The interaction between testosterone and activin-A has also been studied using FSH release from primary cultures of pituitary cells. In this experimental model, testosterone augmented basal and activin-Astimulated FSH release and suppressed the potentiation between activin-A and GnRH (Miyake et al. 1994) . Since several laboratories have reported elevation in LH serum levels after the administration of aromatase inhibitors or antiestrogens (reviewed in Plant 1986), it has been hypothesized that the negative feedback of testosterone on GnRH is mediated by its conversion into E 2 . Indeed, hypothalamic neurons have the biosynthetic machinery to operate this conversion (see Plant 1986 for review). Since the nonaromatizable androgen DHT did not modulate activin-A-stimulated GnRH release, we tested the hypothesis that the effects of testosterone could be due to its conversion to E 2 . However, inhibition of aromatase activity did not influence the effects of testosterone on activin-A-stimulated GnRH release, suggesting that the negative feedback was mediated by testosterone itself. This finding was not completely unexpected since nonaromatizable androgens, such as DHT, are as effective as testosterone in slowing down LH pulse frequency in vivo (reviewed in Plant 1986 ) and in suppressing hypothalamic GnRH release in vitro (Calogero et al. 1993) . In addition, we have been unable to detect any effect of E 2 on hypothalamic GnRH release from the explanted male rat hypothalamus (Calogero et al. 1993) .
In conclusion, this study showed that activin-A stimulates hypothalamic GnRH release and that this effect was overridden by inhibin and, in part, by testosterone. This effect of testosterone does not seem to relate to its possible in vitro aromatization into E 2 . We speculate that activins may modulate the hypothalamic-pituitary-gonadal axis by acting also at the hypothalamic level and the presence of these proteins in the central nervous system regions involved in the release of GnRH assign them a paracrine modulating role.
